10-Q: Sono-Tek Reports Strong Profit Growth Amid Sales Shift

Sono-Tek Corporation announced significant increases in net income and operating profit for the second quarter and first half of fiscal 2026, driven by improved gross margins and reduced operating expenses, despite modest sales growth.

Summary

• Net sales for the second quarter of fiscal 2026 were $5,163,000, up slightly by 0.02% year-over-year, while first-half sales increased 1% to $10,296,000.
• Gross profit for the second quarter rose 3% to $2,590,000, with the gross profit margin expanding to 50.2% from 48.7% in the prior year period.
• First-half gross profit increased 6% to $5,254,000, with the gross profit margin reaching 51.0% compared to 48.8% in the prior year.
• Operating income for the second quarter surged 47% to $421,000, and for the first half, it increased 73% to $905,000.
• Net income for the second quarter was $424,000, up 24% year-over-year, and for the first half, it increased 35% to $909,000.
• Basic earnings per share for both the quarter and six months increased from $0.02 to $0.03 and $0.04 to $0.06, respectively.
• Cash and cash equivalents decreased by $1,370,000 in the first half of fiscal 2026, with net cash used in operating activities increasing significantly to $1,099,000.
• Total equipment and service-related backlog remained robust at $11,210,000 as of August 31, 2025, a 2% decrease from the prior year record but a 50% sequential increase from the first quarter of fiscal 2026.
• The company had no outstanding debt and held $10.6 million in cash, cash equivalents, and marketable securities as of August 31, 2025.
• A customer-requested shipment delay impacted In-Line Coating Systems sales in the second quarter, though first-half sales for this category grew 65% due to high ASP solar coating system shipments.
• Medical sales surged 150% in Q2 and 44% in H1, while Asia Pacific sales increased 153% in Q2 and 74% in H1, driven by medical and alternative energy demand.
• The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, permanently restores 100% bonus depreciation and reinstates immediate expensing of domestic R&D costs, potentially leading to tax refunds and reduced tax payable.

Sentiment

Score: 7

Explanation: The company demonstrated strong profitability growth and margin expansion, coupled with a robust backlog and no outstanding debt. Strategic shift to higher-value systems and growth in medical/APAC markets are positive. However, significant negative cash flow from operations, a large increase in accounts receivable, and high customer concentration with a payment delay introduce notable short-term liquidity concerns.

Positives

• Gross profit margins significantly improved, reaching 50.2% in Q2 and 51.0% in H1, driven by a favorable product mix of mature high ASP systems and reduced costs.
• Operating income increased substantially by 47% in Q2 and 73% in H1, demonstrating strong operating leverage from improved gross profit and decreased operating expenses.
• Net income grew by 24% in Q2 and 35% in H1, reflecting enhanced profitability.
• Backlog remains robust at $11,210,000, with a 50% sequential increase from Q1 fiscal 2026, indicating strong new order momentum, particularly from the medical market.
• No outstanding debt as of August 31, 2025, and a healthy cash, cash equivalents, and marketable securities balance of $10.6 million.
• Medical sales surged 150% in Q2 and 44% in H1, driven by balloon and stent coating systems, highlighting growth in a key market.
• Asia Pacific sales increased sharply by 153% in Q2 and 74% in H1, indicating strong international demand, especially in China, Japan, and South Korea.
• The One Big Beautiful Bill Act (OBBBA) is expected to reduce current tax payable for capital expenditures and may generate tax refunds from retroactive R&D expensing.

Negatives

• Net cash used in operating activities increased significantly to $1,099,000 in the first half of fiscal 2026, compared to $90,000 in the prior year, primarily due to increased accounts receivable and decreased customer deposits.
• Cash and cash equivalents decreased by $1,370,000 in the first half of fiscal 2026.
• Accounts receivable increased by $1,865,000 due to revised payment terms for one customer's $4.4 million order, leading to an anticipated modest two-month delay on a portion of a payment.
• Customer concentration is high, with one customer accounting for 43% of total sales in H1 fiscal 2026 and 59% of outstanding accounts receivable at August 31, 2025.
• Sales of Multi-Axis Coating Systems decreased 41% in H1 fiscal 2026, following strong semiconductor-related orders in the prior year that did not repeat.
• Industrial sales declined significantly by 68% in Q2 and 67% in H1 fiscal 2026, influenced by a large float glass coating order in the prior year that did not repeat.
• U.S. and Canada sales declined 22% in Q2 and 5% in H1 fiscal 2026, reflecting weaker green energy demand from the US.
• Latin America sales declined 45% in Q2 and 46% in H1 fiscal 2026 due to slow activity of PCB fluxing systems in Mexico.

Risks

• General economic and business conditions, including inflationary and supply chain pressures, could adversely affect operations or product demand.
• Political, regulatory, tax, competitive, and technological developments may impact operations or product demand.
• The recovery of the Electronics/Microelectronics and Medical markets, and the rebound of sales to the industrial market, are uncertain.
• Maintaining increased order backlog and the ability to complete large orders on schedule and on budget are critical for future performance.
• The imposition of tariffs could negatively affect profitability and sales.
• Timely development and market acceptance of new products and continued customer validation of coating technologies are essential for growth.
• Adequacy of financing and capacity additions are important for scaling operations.
• The ability to enforce patents is crucial for protecting proprietary technology.
• Maintaining operating leverage and consummating order proposals are key to sustained profitability.
• Continued sales growth in the medical and alternative energy markets is a forward-looking expectation.
• The successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems carries inherent risks.
• Realization of quarterly and annual revenues within the forecasted range of sales guidance is subject to market fluctuations and operational execution.

Future Outlook

The company anticipates wide variations in order flow and shipments from quarter to quarter. It expects a reduction in current tax payable for capital expenditures in fiscal year 2026 due to the permanent restoration of 100% bonus depreciation. The retroactive expensing of R&D costs for tax years beginning after December 31, 2024, may generate tax refunds. The company is evaluating the impact of new accounting pronouncements (ASU 2023-09 and ASU 2024-03) on its financial statements and disclosures.

Management Comments

• Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability.
• Over the last decade, we have shifted our business from primarily selling ultrasonic nozzles and components to providing complete machine solutions and higher-value subsystems to original equipment manufacturers (OEMs).
• This strategy has resulted in significant growth of our average unit selling price, with our larger machines often selling for over $300,000 and system prices sometimes reaching over $1,000,000.
• We expect that we will experience wide variations in both order flow and shipments from quarter to quarter.
• Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to develop thin-film coating technologies that enable better outcomes for our customers products and processes.
• During the past year, we have experienced a shift in customer mix toward larger, more financially stable companies that generally operate under stricter standard payment terms.
• Because we have already collected a significant cash down payment on the order and we anticipate only a modest delay of approximately two months on a portion of the next payment, we accommodated the customer's request. The customer has indicated that they will return to the originally agreed payment schedule thereafter. Based on our long-standing relationship and ongoing communications, we do not currently foresee any collection issues with this customer.

Industry Context

Sono-Tek operates as a global leader in ultrasonic coating systems, serving diverse industries including microelectronics, alternative energy, medical devices, and advanced industrial manufacturing. The company is strategically shifting its business model from selling components to providing complete machine solutions and higher-value subsystems, leading to significantly higher average selling prices. This transition is expanding its addressable market. The company's move into the clean energy sector, focusing on next-gen solar cells, fuel cells, green hydrogen generation, and carbon capture, positions it within a high-growth industry. While the medical market shows strong growth, the electronics/microelectronics sector is experiencing lower semiconductor demand compared to previous elevated levels, reflecting cyclical industry trends. The company's R&D focus and global distribution network are key to maintaining its market leadership and adapting to evolving industry demands.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, and ongoing stock repurchase program. Potential concern from decreased cash and increased accounts receivable.
• Customers: Continued focus on providing complete coating solutions and application consulting services, with expanded testing labs to meet needs.
• Employees: Stock-based compensation expense continues, indicating ongoing incentive programs. Changes in R&D and sales personnel noted due to departures.

Next Steps

• Continue to expand sales capabilities by increasing the direct sales force and adding new distributors and sales representatives.
• Further develop custom solutions for customers through testing labs.
• Evaluate the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) and ASU 2024-03 (Disaggregation of Income Statement Expenses) on consolidated financial statements and disclosures.
• Manage the resolution of the customer payment delay and monitor accounts receivable collection.

Key Dates

Recommendation

While Sono-Tek delivered strong profitability growth, margin expansion, and a healthy backlog, the significant negative cash flow from operations and the increase in accounts receivable due to a customer payment delay are material concerns. The high customer concentration further amplifies this risk. The strategic shift to higher-value systems and growth in key markets like medical and alternative energy are positive long-term indicators. However, until there is clearer resolution on the cash flow and accounts receivable issues, a 'hold' recommendation is prudent for a seasoned investor, allowing for observation of how these short-term liquidity challenges are managed and if the underlying operational strengths can translate into improved cash generation.

Keywords

ultrasonic coating systems, thin film coatings, microelectronics, alternative energy, medical devices, industrial manufacturing, R&D, OEM systems, gross profit, operating income, net income, backlog, cash flow, accounts receivable, customer concentration, tax incentives, bonus depreciation, R&D expensing, stock repurchase